Lilly and Amylin clarify Byetta pancreatitis risk
This article was originally published in Scrip
Six patients who have received Lillyand Amylin's injectable type 2 diabetes drug Byetta (exenatide) and who have also had pancreatitis have died so far, the companies have revealed in a conference call.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.